General Information of Target

Target ID LDTP01670
Target Name Interleukin-33 (IL33)
Gene Name IL33
Gene ID 90865
Synonyms
C9orf26; IL1F11; NFHEV; Interleukin-33; IL-33; Interleukin-1 family member 11; IL-1F11; Nuclear factor from high endothelial venules; NF-HEV) [Cleaved into: Interleukin-33; 95-270; Interleukin-33; 99-270; Interleukin-33; 109-270)]
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MKPKMKYSTNKISTAKWKNTASKALCFKLGKSQQKAKEVCPMYFMKLRSGLMIKKEACYF
RRETTKRPSLKTGRKHKRHLVLAACQQQSTVECFAFGISGVQKYTRALHDSSITGISPIT
EYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGK
MLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFI
GVKDNHLALIKVDSSENLCTENILFKLSET
Target Type
Clinical trial
Target Bioclass
Cytokine and receptor
Family
IL-1 family
Subcellular location
Nucleus
Function
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as an enhancer of polarization of alternatively activated macrophages. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury. Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages.; In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets. This form is rapidely lost upon angiogenic or pro-inflammatory activation.
TTD ID
T23797
Uniprot ID
O95760
DrugMap ID
TT5MD4P
Ensemble ID
ENST00000381434.7
HGNC ID
HGNC:16028
ChEMBL ID
CHEMBL4630890

Target Site Mutations in Different Cell Lines

Cell line Mutation details Probe for labeling this protein in this cell
COLO792 SNV: p.E269K .
HG3 SNV: p.V101L .
KELLY SNV: p.K266N .
MCC13 SNV: p.R61K .
RKO Deletion: p.K55RfsTer16 .

Probe(s) Labeling This Target

ABPP Probe
Click To Hide/Show 1 Probe Related to This Target
Probe name Structure Binding Site(Ratio) Interaction ID Ref
DBIA
 Probe Info 
C40(6.02); C259(4.62)  LDD3346  [1]

Competitor(s) Related to This Target

Competitor ID Name Cell line Binding Site(Ratio) Interaction ID Ref
 LDCM0022  KB02 Caov-3 C259(1.10)  LDD2295  [1]
 LDCM0023  KB03 COLO 320 C40(0.97); C259(1.25)  LDD2720  [1]
 LDCM0024  KB05 NCI-H1666 C40(6.02); C259(4.62)  LDD3346  [1]

References

1 DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22.
Mass spectrometry data entry: PXD047840